PS01.185: STATUS OF SUBCARINAL LYMPH NODE METASTASIS AND DISSECTION STRATEGY FOR THORACIC ESOPHAGEAL CARCINOMA

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 102-102
Author(s):  
Long-Qi Chen ◽  
Yun-Cang Wang ◽  
Han-Yu Deng

Abstract Background The subcarinal lymph node metastasis, although with the debate whether it is a characteristic of lung cancer or esophageal cancer, is prevalent in esophageal carcinoma, and with the incidence of 4.1%-17.5% according to some estimates. The aim of this study is to assess the pattern of subcarinal lymph node metastasis and the dissection strategy for thoracic esophageal carcinoma. Methods A large cohort, retrospective study was conducted on 596 patients with thoracic esophageal carcinoma treated from July 2008 to December 2010. The metastasis rate of subcarinal lymph node was investigated. Survival of patients treated by different dissection strategies was compared. The effectiveness index was used to assess the outcome of subcarinal lymph node dissection. Results Of 596 patients, 447 had documented subcarinal lymph node dissection (75.0%). According to whether the subcarinal lymph node was harvested or not, they were divided into two groups: dissection group (n = 447) and non-dissection group (n = 149). Their 5-year survival rates were 48.3 ± 1.7 months for dissection group vs. 38.1 ± 2.8 months for non-dissection group (P < 0.001). The overall subcarinal node metastasis rate in the dissection group was 12.5% (56/447). Based on the status of subcarinal nodes, there was a significant difference in survival, 52.3 ± 1.8 months with negative nodes (n = 391) compared to 19.9 ± 2.2 months for those with positive nodes (n = 56) (P < 0.001). Subgroup analysis was further conducted for the positive subcarinal nodes patients. The metastasis rates in patients with upper, middle and lower esophageal cancer were 5.4%, 15.1% and 10.1%, respectively (P < 0.05 for comparison between patients with upper and other segments). The effectiveness indices for these three groups of patients were as 0%, 4.8% and 27.2%, respectively. The metastasis rates for T0, T1, T2, T3 and T4 esophageal carcinoma were 0%, 0%, 3.5%, 10.7% and 19.0%, respectively (P < 0.05 for comparison between T0/T1/T2 and T3/T4 tumors. Conclusion Thoracic esophageal carcinoma has a high incidence of subcarinal lymph node metastasis, especially among those with middle and lower esophageal cancer, and for deeper invaded tumors. Therefore, for middle and lower esophageal tumors, subcarinal lymph node dissection is necessary, whereas for T1/2 upper esophageal tumors, subcarinal lymph node dissection can be spared from subcarinal lymph node dissection. Disclosure All authors have declared no conflicts of interest.

Esophagus ◽  
2021 ◽  
Author(s):  
Jun Shibamoto ◽  
Hitoshi Fujiwara ◽  
Hirotaka Konishi ◽  
Atsushi Shiozaki ◽  
Takuma Ohashi ◽  
...  

Abstract Background The aim of the present study was to evaluate subcarinal lymph node dissection in transmediastinal radical esophagectomy and subcarinal lymph node metastasis in patients with esophageal cancer. Methods Three hundred and twenty-three patients with primary esophageal cancer who underwent transmediastinal or transthoracic esophagectomy with radical two- or three-field lymph node dissection were retrospectively investigated. The clinicopathological characteristics of patients with subcarinal lymph node metastasis were analyzed in detail. Results The median of dissected subcarinal lymph nodes in transmediastinal and transthoracic esophagectomy groups was 6 and 7, respectively, and there was no significant difference between the two groups (p = 0.12). Of all patients, 26 (8.0%) were pathologically diagnosed as positive for subcarinal lymph node metastasis, whereas only 7 (26.9%) of those with metastasis were preoperatively diagnosed as positive. In addition, all patients with subcarinal lymph node metastasis had other non-subcarinal lymph node metastasis. By univariate analysis, subcarinal lymph node metastasis was found in larger (≥ 30 mm) and deeper (T3/T4a) primary lesions (p = 0.02 and 0.02, respectively), but it was not found in 49 patients with the primary lesion located in the upper thoracic esophagus. Conclusions Subcarinal lymph nodes can be dissected in transmediastinal esophagectomy, almost equivalent to transthoracic esophagectomy. The tumor size, depth, and location may be predictive factors for subcarinal lymph node metastasis.


1998 ◽  
Vol 48 (6) ◽  
pp. 447-453
Author(s):  
Tetsushi Ogawa ◽  
Susumu Ohwada ◽  
Kenji Kawashima ◽  
Izumi Takeyoshi ◽  
Yoshiyuki Kawashima ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Peng Qie ◽  
Qifan Yin ◽  
Xuejiao Xun ◽  
Yongbin Song ◽  
Shaohui Zhou ◽  
...  

Abstract Background Esophageal squamous cell carcinoma(ESCC) is one of the most common tumors worldwide. Esophagectomy with three-field lymph node dissection(3FLND) is the radical surgical procedure for esophageal cancer. However, 3FLND is not widely used due to it’s higher mortality rate and higher incidence of postoperative complications. There is an urgent need to identify novel biomarkers that can guide the most proper lymph-node dissection in esophageal cancer patients. Method Ninety-two patients with thoracic ESCC undergoing 3FLND were enrolled into our study from the Department of Thoracic Surgery of the Fourth Hospital affiliated to the Hebei Medical University and Hebei General Hospital between Jun 2011 and Dec 2015. Retrospectively collected data from these 92 patients was used to explore the relationship between the lymph-node metastasis、recurrence and the SPRY4-IT1 expression level and to determine whether 3FLND should be performed in patients with thoracic ESCC. Results The findings revealed that the SPRY4-IT1 expression was significantly higher in esophageal cancer tissues than in adjacent noncancerous tissues. (P < 0.01). Furthermore, the high expression of SPRY4-IT1 was significantly correlated with tumor differentiation (P = 0.029), T classification (P = 0.013), lymph node metastasis(P = 0.022) and pathological stage (P = 0.001). The increased expression of SPRY4-IT1 was associated with a higher risk of cervical and superior mediastinal lymph-node metastasis(P = 0.039).However, no significant association was observed between the risk of cervical and superior mediastinal lymph-node recurrence and the SPRY4-IT1 expression level in the thoracic ESCC patients performed 3FLND(P = 0.509). Conclusions Our data support the assumption that the high expression of SPRY4-IT1 is associated with a high risk of lymph node metastasis and it has potential application as a indicator for guiding on three-field lymph node dissection in patients with thoracic ESCC. Randomized controlled trials with a large cohort of patients will be needed to confirm this conclusion in the future.


2020 ◽  
Author(s):  
Peng Qie ◽  
Qifan Yin ◽  
Xuejiao Xun ◽  
Yongbin Song ◽  
Shaohui Zhou ◽  
...  

Abstract Backgroup:Esophageal squamous cell carcinoma(ESCC) is one of the most common tumors worldwide. Esophagectomy with three-field lymph node dissection(3FLND) is the radical surgical procedure for esophageal cancer. However, 3FLND is not widely used due to it’s higher mortality rate and higher incidence of postoperative complications. There is an urgent need to identify novel biomarkers that can guide the most proper lymph-node dissection in esophageal cancer patients.Method:Ninety-two patients with thoracic ESCC undergoing 3FLND were enrolled into our study from the Department of Thoracic Surgery of the Fourth Hospital affiliated to the Hebei Medical University and Hebei General Hospital between Jun 2011 and Dec 2015. Retrospectively collected data from these 92 patients was used to explore the relationship between the lymph-node metastasis、recurrence and the SPRY4-IT1 expression level and to determine whether 3FLND should be performed in patients with thoracic ESCC. Results: The findings revealed that the SPRY4-IT1 expression was significantly higher in esophageal cancer tissues than in adjacent noncancerous tissues. (P<0.01). Furthermore, the high expression of SPRY4-IT1 was significantly correlated with tumor differentiation (P=0.029), T classification (P=0.013), lymph node metastasis(P=0.022) and pathological stage (P=0.001). The increased expression of SPRY4-IT1 was associated with a higher risk of cervical and superior mediastinal lymph-node metastasis(P = 0.039).However, no significant association was observed between the risk of cervical and superior mediastinal lymph-node recurrence and the SPRY4-IT1 expression level in the thoracic ESCC patients performed 3FLND(P=0.509). Conclusions: Our data support the assumption that the high expression of SPRY4-IT1 is associated with a high risk of lymph node metastasis and it has potential application as a indicator for guiding on three-field lymph node dissection in patients with thoracic ESCC. Randomized controlled trials with a large cohort of patients will be needed to confirm this conclusion in the future.


Oncotarget ◽  
2017 ◽  
Vol 8 (69) ◽  
pp. 113817-113827 ◽  
Author(s):  
Jie Hu ◽  
Fei-Yu Chen ◽  
Kai-Qian Zhou ◽  
Cheng Zhou ◽  
Ya Cao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document